ACROMETA Group Limited 2026 AGM: Resolutions, Poll Results, and Share Schemes Approved

AcroMeta Group Limited Announces Key Decisions at 2026 Annual General Meeting

AcroMeta Group Limited (SGX:43F) held its Annual General Meeting (AGM) on 23 January 2026, where several significant resolutions were passed. Investors and shareholders should note the following crucial developments, many of which could impact the company’s share value and future direction:

1. Adoption of Audited Financial Statements

The AGM approved the audited financial statements for the year ended 30 September 2025, together with the Directors’ Statement and Independent Auditors’ Report. This signals a clean bill of health for AcroMeta’s financials, with no shareholder questions raised about the statements or audit process.

2. Board Changes and Director Re-Election

Re-election of Mr Chan Tze Choong Eric: Mr Chan was re-elected as an Independent Director. He will continue as Chairman of the Remuneration Committee and as a member of both the Audit and Nominating Committees. The Board reaffirmed his independence under SGX Catalist Rules, which is important for corporate governance.
Retirement of Mr Cheong Keng Chuan, Alfred: Mr Cheong retired and did not seek re-election. He ceased to be Lead Independent Director and Chairman of the Audit Committee. The Board thanked him for his contributions, indicating a transition in leadership and committee structure.

3. Directors’ Fees Approved

Shareholders approved a total of S\$105,000 in directors’ fees for FY ending 30 September 2026, to be paid in arrears. This reflects the company’s commitment to rewarding governance and oversight.

4. Auditor Re-Appointment

PKF-CAP LLP was re-appointed as AcroMeta’s external auditor, with remuneration to be fixed by the directors. The continuity of audit oversight ensures financial reliability and stability.

5. Share Issuance Authorities

General Authority to Issue Shares: The Board is empowered to issue shares and convertible securities up to 100% of total issued shares, with a cap of 50% for non-pro-rata issuance. This authority provides flexibility for fundraising and strategic deals, which could affect share dilution and price.
Performance Share Plan 2025: Directors are authorised to grant awards and issue shares under the AcroMeta Performance Share Plan 2025, up to 15% of issued shares. This aligns management incentives with shareholder value but may introduce dilution if exercised.

6. Share Purchase Mandate Renewal

The Board received authority to repurchase up to 10% of issued shares, either through market or off-market purchases. Maximum purchase price is set at 105% (market) or 120% (off-market) of the average closing price. This buyback capability can support share prices and signal confidence in the company.

7. Related Party Transactions and Performance Share Awards

Participation by Mr Levin Lee Keng Weng (Controlling Shareholder): Shareholders approved Mr Lee’s participation in the Performance Share Plan 2025, and the grant of up to 8,000,000 shares as an award, contingent on the resolution’s passage. This is a substantial award to a controlling shareholder and may be price sensitive, especially if perceived as aligning interests or as excessive dilution.

8. New Employee Share Option Scheme (ESOS) 2026

Scheme Adoption: Shareholders approved the AcroMeta Employee Share Option Scheme 2026, allowing options for employees and directors to subscribe for shares (up to 15% of issued shares, excluding treasury shares and subsidiary holdings). This is designed to attract and retain talent, but investors should watch for dilution effects if options are exercised.
Granting Options at a Discount: The Board was given authority to grant options under ESOS 2026 at discounts of up to 20% off market price. This is a potentially price-sensitive move, as it could incentivize rapid option exercises and introduce dilution.

9. Poll Results and Shareholder Support

All resolutions were passed with strong majorities, indicating broad shareholder support for the Board’s proposals. Notably, resolutions involving related party transactions and performance share awards saw abstentions from interested parties, as required.

Potential Price Sensitive Highlights

Share Issuance Authority: The ability to issue up to 100% of shares, including 50% non-pro-rata, could lead to significant dilution if exercised, potentially impacting share price.
Performance Share Plan Awards: The grant of up to 8,000,000 shares to Mr Levin Lee, a controlling shareholder, is material and could affect perceptions of governance and share value.
Share Buyback Mandate: The renewed buyback authority gives AcroMeta flexibility to support its share price or return capital to shareholders.
Employee Share Option Scheme: The new ESOS, especially with up to 20% discount on options, may incentivize employee retention but also introduces dilution risk.

Conclusion

The 2026 AGM of AcroMeta Group Limited was marked by substantial shareholder support for the Board’s proposals, including expanded share issuance and buyback authorities, adoption of new incentive plans, and approval of related party performance share awards. These resolutions provide management with tools for growth, fundraising, and talent retention, but investors should closely monitor potential dilution and governance implications.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own analysis and consult with professional advisers before making investment decisions. AcroMeta’s share price may be impacted by the resolutions passed at the AGM, but future performance and market reactions cannot be guaranteed.